| Literature DB >> 24833052 |
Emanuela Lonardi1, Kristof Moonens2, Lieven Buts3, Arjen R de Boer4, Johan D M Olsson5, Manfred S Weiss6, Emeline Fabre7, Yann Guérardel8, André M Deelder9, Stefan Oscarson10, Manfred Wuhrer11, Julie Bouckaert12.
Abstract
Fimbriae are long, proteinaceous adhesion organelles expressed on the bacterial envelope, evolutionarily adapted by Escherichia coli strains for the colonization of epithelial linings. Using glycan arrays of the Consortium for Functional Glycomics (CFG), the lectin domains were screened of the fimbrial adhesins F17G and FedF from enterotoxigenic E. coli (ETEC) and of the FimH adhesin from uropathogenic E. coli. This has led to the discovery of a more specific receptor for F17G, GlcNAcb1,3Gal. No significant differences emerged from the glycan binding profiles of the F17G lectin domains from five different E. coli strains. However, strain-dependent amino acid variations, predominantly towards the positively charged arginine, were indicated by sulfate binding in FedF and F17G crystal structures. For FedF, no significant binders could be observed on the CFG glycan array. Hence, a shotgun array was generated from microvilli scrapings of the distal jejunum of a 3-week old piglet about to be weaned. On this array, the blood group A type 1 hexasaccharide emerged as a receptor for the FedF lectin domain and remarkably also for F18-fimbriated E. coli. F17G was found to selectively recognize glycan species with a terminal GlcNAc, typifying intestinal mucins. In conclusion, F17G and FedF recognize long glycan sequences that could only be identified using the shotgun approach. Interestingly, ETEC strains display a large capacity to adapt their fimbrial adhesins to ecological niches via charge-driven interactions, congruent with binding to thick mucosal surfaces displaying an acidic gradient along the intestinal tract.Entities:
Year: 2013 PMID: 24833052 PMCID: PMC3960879 DOI: 10.3390/biology2030894
Source DB: PubMed Journal: Biology (Basel) ISSN: 2079-7737
Binding of five F17G variants on the Consortium for Functional Glycomics (CFG) mammalian printed glycan array. Values are Relative Fluorescence Units (RFU), averaged over six replicates, for the best glycan binders to five F17G variant sequences on the CFG glycan array version 2. Standard errors of the means (SEM) are presented in parentheses.
| N° | Glycan name | F17aG | F17bG | F17dG | F17eG | F17fG |
|---|---|---|---|---|---|---|
| 167 | GlcNAcβ1,3Galβ1,4Glcβ-Sp0 | 57,013 (5,191) | 13,149 (2,286) | 29,181 (3,281) | 54,005 (5,715) | 26,336 (7,255) |
| 165 | GlcNAcβ1-3Galβ1,4GlcNAcβ-Sp8 | 51,880 (5,023) | 15,483 (1,729) | 17,991 (4,401) | 49,223 (5,377) | 28,888 (6,925) |
| 160 | GlcNAcβ1,3(GlcNAcβ1,6)Galβ1,4GlcNAcβ-Sp8 | 44,391 (3,949) | 21,630 (2,490) | 17,195 (3,442) | 41,907 (4,694) | 37,083 (5,973) |
| 159 | GlcNAcβ1,3(GlcNAcβ1,6)GalNAcα-Sp8 | 35,858 (4,079) | 12,183 (1,524) | 23,756 (2,105) | 46,840 (6,520) | 37,083 (1,197) |
| 162 | GlcNAcβ1,3Galβ-Sp8 | 32,288 (4,175) | 16,310 (1,907) | 16,277 (9,959) | 38,836 (5,631) | 27,648 (1,137) |
| 161 | GlcNAcβ1,3GalNAcα-Sp8 | 25,971 (3,174) | 15,182 (2,925) | 6,635 (2,735) | 33,330 (7,321) | 10,999 (2,929) |
| 88 | GalNAcβ1,3GalNAcα-Sp8 | 24,610 (3,462) | 17,169 (4,228) | 11,034 (1204) | 50,791 (5,749) | 10,691 (3,009) |
| 25 | (GlcNAcβ1,3(GlcNAcβ1,6)GlcNAcβ1,4)GlcNAc-Sp8 | 20,305 (2,023) | 6,148 (1,367) | 8,080 (1,518) | 50,775 (6,375) | 2,992 (992) |
| 21 | GlcNAcβ-Sp0 | 15,621 (2,697) | 14,972 (2,705) | 3,377 (643) | 34,825 (6,475) | 5,354 (1,572) |
| 22 | GlcNAcβ-Sp8 | 22,909 (3,087) | 12,289 (1,168) | 2,514 (365) | 31,863 (4,615) | 10,738 (2,670) |
| 174 | GlcNAcβ1,6(Galβ1,3)GalNAcα-Sp8 | 12,541 (1,115) | 6,017 (587) | 3,492 (658) | 46,930 5,852 | 3,206(997) |
| 170 | GlcNAcβ1,4Galβ1,4GlcNAcβ-Sp8 | 12,499 (1,921) | 13,001 (2,039) | 1,056 (190) | 39,794 (6,245) | 7,176 (2,338) |
| 175 | GlcNAcβ1,6GalNAcα-Sp8 | 11,120 (1,871) | 6,683 (947) | 2,432 (406) | 43,848 (4,140) | 26,522 (11,365) |
| 166 | GlcNAcβ1,3Galβ1,4GlcNAcβ1,3Galβ1,4GlcNAcβ-Sp0 | 10,917 (811) | 7,563 (2,744) | 3,599 (772) | 43,425 (4,065) | 4,334 (856) |
| 121 | Galβ1,3(GlcNAcβ1,6)GalNAcα-Sp8 | 10,256 (1,410) | 6,215 (1,046) | 3,850 (364) | 50,893 (5,540) | 3,195 (811) |
| 176 | GlcNAcβ1,6Galβ1,4GlcNAcβ-Sp8 | 9,029 (1,096) | 5,372 (746) | 5,119 (1,633) | 40,973 (6,555) | 2,269 (561) |
| 163 | GlcNAcβ1,3Galβ1,3GalNAcα-Sp8 | 7,713 (866) | 10,655 (880) | 3,999 (1,481) | 47,984 (3,178) | 31,661 (2,807) |
| 169 | GlcNAcβ1,4(GlcNAcβ1,6)GalNAcα-Sp8 | 4,520 (2,808) | 12,960 (1,692) | 1,680 (92) | 38,200 (2,394) | 19,830 (4,279) |
| 158 | GlcNAcβ1,2Galβ1,3GalNAcα-Sp8 | 5,082 (4,924) | 1,016 (239) | 75 (35) | 305 (148) | 563 (125) |
| 23 | GlcNH2β-Sp8 | 554 (117) | 7,281 (1,506) | 1,950 (1,358) | 548 (256) | 1,385 (464) |
| 152 | Galβ1,4GlcNAcβ-Sp0 | 1,703 (1,070) | 1,974 (289) | 249 (94) | 19,659 (4,594) | 1,279 (106) |
| 173 | GlcNAcβ1,4GlcNAcβ1,4GlcNAcβ-Sp8 | 848 (88) | 2,860 (706) | 1,690 (251) | 5,689 (1,085) | 2,418 (613) |
| 148 | Galβ1,4GlcNAcβ1,3Galβ1,4Glcβ-Sp0 | 391 (24) | 1,090 (262) | 919 (375) | 3,942 (857) | 663 (146) |
| 213 | Neu5Acα2,3(Neu5Acα2,6)GalNAcα-Sp8 | 4,527 (4,043) | 4,331 (1,760) | 1,388 (1,162) | 1,229 (1,162) | 1,717 (229) |
Sp0 = -OCH2CH2NH-; Sp8 = -OCH2CH2CH2CH2NH-.
Figure 1CFG synthetic glycan array showing the F17aG specificity profile (all data are available in a browsable format [27].
Figure 2(a) Natural glycan array screening for F17G(4Lys) variants a (upper) and b (lower); (b) Natural glycan array concentration-dependent screening for F17bG with His-tag. Mouse anti-His antibodies, instead of polyclonal rabbit anti-F17G, were here used as primary antibodies, in order to reduce the background level observed in (a) for F17bG.
Steady-state affinities of variant F17G receptor-binding domains. The value of the dissociation constant Kd is expressed in mM for cases where a good fit could be obtained for at least three related experiments. * pNP-GlcNAc: paranitrophenyl β-GlcNAc, GlcNH2-MurNAc: glucosamine β1,4 N-actetylmuramic acid (from peptidoglycan), GM1 ganglioside: from ovine brain (Avanti Polar Lipids). Affinity ranges from high to low are indicated: +++ Kd = 10−4 M; ++ Kd = 10−3 M; + Kd = 10−2 M; - does not bind.
| Carbohydrate | F17aG | F17bG | F17fG | F17eG |
|---|---|---|---|---|
| GlcNAcβ1,3Gal | +++ 0.66 | ++ | +++ | +++ 0.28 |
| GlcNAcβ1,4GlcNAc (chitobiose) | ++ 3.3 | ++ | ++ | |
| GlcNAc (
| ++ 1.2 | ++ | ++ | |
| Me β | ++ 1.2 | |||
| Me α | + 9.8 | |||
| GlcNAcβ1,2Gal | ++ 4.2 | ++ 2.0 | ||
| GlcNAcβ1,4Gal | ++ 3.3 | ++ 2.7 | ||
| GlcNAcβ1,6Gal | ++ 2.8 | ++ 3.8 | ||
| GlcNAcβ1,2Manα1,6(GlcNAcβ1,2Manα1,3)Man | ++ 3.0 | ++ 3.0 | ||
| Gal β1,4 GlcNAc | ++ | ++ | ||
| Galβ1,6GlcNAc | + | + | + | ++ |
| Galβ1,3GlcNAcβ 1,3Galβ1,4Glc | - | |||
| Galβ1,4GlcNAcβ 1,3Gal β1,4Glc | + | |||
| Fucα1,2Galβ1,3GlcNAcβ1,3Galβ1,4Glc | - | |||
| Neu5Acα2,6Galβ1,4Glc | ++ | |||
| pNP-GlcNAc * | +++ | + | ++ | |
| ++ | + | ++ | ||
| - | - | - | ||
| Galβ1,3GalNAc | + | + | ||
| GlcNAc6SO3− | + | - | ++ | |
| GlcNAc3SO3− | ++ | ++ | - | |
| GlcNAc6PO32− | - | + | - | |
| GlcNH2-MurNAc * | + | + | - | |
| Neu5Acα2,3Galβ1,3(Neu5Acα2,6)GlcNAcβ1,3Gal β1,4Glc | + | + | - | |
| LeY | - | - | ++ | |
| GM1 ganglioside * | - | + | - | |
| Neu5Acα2,3Galβ1,4GlcNAcβ1,2 Man | + | + | ||
| GalNAcβ1,4GlcNAcβ1-methoxy phenyl | ++ |
Figure 3In F17bG crystal structures, the reducing end galactose (Gal) residue of GlcNAcβ1,3Gal (Φ = −67.3°/Ψ = 69.6°) stacks its hydrophobic B-face (at C4) onto the side chain of Trp109 (PDB entry 4K0O). The mannose (Man) residue in GlcNAcβ1,2Man occupies a similar position (Φ = −117.8°/Ψ = 104.4°), but stacks less efficiently because of its smaller apolar region (PDB entry 3FFO). The reducing GlcNAc residue in chitobiose (GlcNAcβ1,4GlcNAc) adopts a third, distinct orientation (Φ = −79.5°/Ψ = −142.6°) in the same site. The N-acetyl group of the second GlcNAc points away from the protein and is not likely to contribute to the binding (PDB entry 2BS7). Glycosidic angles Φ and Ψ are defined for 1,2 linkages: O5:C1-O:C2' and C1:O-C2':C3'; for 1,3 linkages: O5:C1-O:C3' and C1:O-C3':C4'; for 1,4 linkages: O5:C1-O:C4' and C1:O-C4':C5'.
Figure 4Superpositioning of the carbohydrate-binding sites of F17aG (yellow) and F17bG (white), highlighting the impact of the Ala113 insertion in F17aG. Residues of F17bG are labelled in italics. A bound GlcNAcβ1,3Gal ligand is shown in magenta to indicate the extent of the disaccharide-binding site.
Figure 5Shotgun glycan array screening (a) for the FedF lectin domain and (b) for F18 fimbriated E. coli.
Figure 6Amino acid analyses of E. coli strain-variable residues for the sequences (a, b, c) corresponding to the crystallized lectin domains (d, e, f) of F17bG (PDB 4K0O), FedF (PDB 4TST) and FimH (PDB 2VCO). Intraspecies variant residues are indicated in red, with those variable residues that also bind the glycan (near the non-reducing end) highlighted in orange. Residues ligating the recognized oligosaccharide are depicted in green. Sulfate-binding residues are highlighted in blue, in cyan when also variant or in fuchsia when also sugar-binding. Variations in charged residues are underpinned with a star (*). Sulfate ions S1–S4 have been identified in the different crystal structures.
CFG glycan array with the responses of the FedF lectin domain towards charged sugars. Sulfated sugars that gave RFU signals higher than their standard deviation on the CFG glycan array (experiment 399) are listed (RFU is the averaged Relative Fluorescence Units for the six replicates of each glycan and SEM (standard error of the mean) is the standard deviation (Stdev) divided by the square root of the six replicates).
| candidate sulphated lactose structures | RFU | Stdev | SEM | |
|---|---|---|---|---|
| [3OSO3][6OSO3]Galβ1,4[6OSO3]GlcNAc | 10,388 | 3,852 | 1,573 | |
| [3OSO3]Galβ1,4[6OSO3]GlcNAc | 6,806 | 1,854 | 757 | |
| [6OSO3]Galβ1,4[6OSO3]Glc | 5,405 | 2,430 | 992 | |
| [3OSO3][6OSO3]Galβ1,4GlcNAc | 4,733 | 1,157 | 472 | |
| [4OSO3][6OSO3]Galβ1,4GlcNAc | 4,568 | 2,057 | 840 | |
| [3OSO3]Galβ1,4[6OSO3]Glc | 4,073 | 1,515 | 618 | |